The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Applications will be reviewed in the first instance by NHS England and the AHSN Network to assess deliverability and potential impact in addressing the five national diabetes priorities.
Applicants considered suitable to progress to the Diabetes Hothouse will be invited to an event on 22 November in London to present their proposals to representatives from the five pharmaceutical companies. Colleagues from both the ABPI and the AHSN Network to will be on hand to help applicants explore ideas for potential collaboration partners if support is required.
No upper or lower limit has been set for the collaboration projects. This will be based on merit, and will vary depending on both the innovation itself and how the project is designed. The decision as to whether to partner on a project will be at the discretion of the individual participating companies.
Successful applicants will be jointly supported by NHS England and the interested pharmaceutical company(ies), and the AHSN Network where required.
More on NHS England’s diabetes programme: https://www.england.nhs.uk/diabetes/